SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ImmunoGen
IMGN 31.230.0%Feb 26 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Gary Mohilner who wrote (5522)1/5/2013 8:59:50 PM
From: Gary Mohilner   of 5665
 
I hope the few posting here are following the much more active board on Investor's Village. If you are, pay particular attention to JV's recent posts on T-DM1's use in other than breast cancer. There is little doubt in my mind that Roche will grow this drug into a $10 billion or more product annually and even at under 5%, IMGN would be worth triple digits on the strength of T-DM1 alone. If you read further, you'll see where many other products continue to advance, and I strongly believe that a few years from now other drugs filing, or near filing NDA's or BLA's will be the major topic of discussion, earning hundreds of millions from T-DM1 will simply be a fact.

Gary
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News